These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22578147)

  • 1. Choice of prognostic estimators in joint models by estimating differences of expected conditional Kullback-Leibler risks.
    Commenges D; Liquet B; Proust-Lima C
    Biometrics; 2012 Jun; 68(2):380-7. PubMed ID: 22578147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Information estimators for weighted observations.
    Hino H; Murata N
    Neural Netw; 2013 Oct; 46():260-75. PubMed ID: 23859828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A universal approximate cross-validation criterion for regular risk functions.
    Commenges D; Proust-Lima C; Samieri C; Liquet B
    Int J Biostat; 2015 May; 11(1):51-67. PubMed ID: 25849800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: a joint modeling approach.
    Proust-Lima C; Taylor JM
    Biostatistics; 2009 Jul; 10(3):535-49. PubMed ID: 19369642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
    Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
    J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic factors of localised, locally advanced or metastatic prostate cancer].
    Joly F; Henry-Amar M
    Bull Cancer; 2007 Jul; 94(7 Suppl):F35-43. PubMed ID: 17845992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating prognostic accuracy of biomarkers under competing risk.
    Zheng Y; Cai T; Jin Y; Feng Z
    Biometrics; 2012 Jun; 68(2):388-96. PubMed ID: 22150576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms.
    Shariat SF; Park S; Trinh QD; Roehrborn CG; Slawin KM; Karakiewicz PI
    J Urol; 2007 Oct; 178(4 Pt 1):1229-36; discussion 1236-7. PubMed ID: 17698116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes.
    Pauler DK; Finkelstein DM
    Stat Med; 2002 Dec; 21(24):3897-911. PubMed ID: 12483774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer.
    Bauer JJ; Connelly RR; Seterhenn IA; Deausen J; Srivastava S; McLeod DG; Moul JW
    J Urol; 1998 Mar; 159(3):929-33. PubMed ID: 9474185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An empirical approach to model selection through validation for censored survival data.
    Choi I; Wells BJ; Yu C; Kattan MW
    J Biomed Inform; 2011 Aug; 44(4):595-606. PubMed ID: 21335102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of three risk assessment tools in Australian patients with prostate cancer.
    Tamblyn DJ; Chopra S; Yu C; Kattan MW; Pinnock C; Kopsaftis T
    BJU Int; 2011 Nov; 108 Suppl 2():51-6. PubMed ID: 22085129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients.
    Gates JD; Carmichael MG; Benavides LC; Holmes JP; Hueman MT; Woll MM; Ioannides CG; Robson CH; McLeod DG; Ponniah S; Peoples GE
    J Am Coll Surg; 2009 Feb; 208(2):193-201. PubMed ID: 19228530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating survival and association in a semicompeting risks model.
    Lakhal L; Rivest LP; Abdous B
    Biometrics; 2008 Mar; 64(1):180-8. PubMed ID: 17645782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model selection for extended quasi-likelihood models in small samples.
    Hurvich CM; Tsai CL
    Biometrics; 1995 Sep; 51(3):1077-84. PubMed ID: 7548692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semiparametric analysis of survival data with left truncation and dependent right censoring.
    Jiang H; Fine JP; Chappell R
    Biometrics; 2005 Jun; 61(2):567-75. PubMed ID: 16011706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian variable selection method for censored survival data.
    Faraggi D; Simon R
    Biometrics; 1998 Dec; 54(4):1475-85. PubMed ID: 9883546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene based prediction of clinically localized prostate cancer progression after radical prostatectomy.
    Talantov D; Jatkoe TA; Böhm M; Zhang Y; Ferguson AM; Stricker PD; Kattan MW; Sutherland RL; Kench JG; Wang Y; Henshall SM
    J Urol; 2010 Oct; 184(4):1521-8. PubMed ID: 20723930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.
    Hueman MT; Dehqanzada ZA; Novak TE; Gurney JM; Woll MM; Ryan GB; Storrer CE; Fisher C; McLeod DG; Ioannides CG; Ponniah S; Peoples GE
    Clin Cancer Res; 2005 Oct; 11(20):7470-9. PubMed ID: 16243821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.